Bone health in cancer: ESMO Clinical Practice Guidelines
Robert E. Coleman(University of Sheffield), Peyman Hadji(Philipps University of Marburg), Jean‐Jacques Body(Centre Hospitalier Universitaire Brugmann), Daniele Santini(Università Campus Bio-Medico), Edward Chow(University of Toronto), Evangelos Terpos(National and Kapodistrian University of Athens), Stéphane Oudard(Délégation Paris 5), Øyvind S. Bruland(University of Oslo), Patrick Flamen(Université Libre de Bruxelles), Andreas Kurth(Johannes Gutenberg University Mainz), Catherine Van Poznak(University of Michigan–Ann Arbor), Matti Aapro(Clinique de Genolier), Karin Jordan(Heidelberg University)
Cited by 512Open Access
Abstract
•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment.•Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications.•The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.
Related Papers
No related papers found
Powered by citation graph analysis